{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:10:25Z","timestamp":1769152225393,"version":"3.49.0"},"reference-count":11,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2005,2,7]],"date-time":"2005-02-07T00:00:00Z","timestamp":1107734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Institutes of Health Comprehensive Sickle Cell Center Program Project","award":["G020252"],"award-info":[{"award-number":["G020252"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2005,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Experience with the use of central venous access device (CVAD) in children with sickle cell disease (SCD) on hypertransfusion is limited and published studies report wide variability in the rates of CVAD\u2010associated complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>In this study, a total of 18 Cathlink\u00ae 20 ports (Bard Access systems, Salt Lake City, UT) were implanted in 15 patients aged 7\u201320 years with SCD for 19, 230 catheter patient days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No peri\u2010operative complications were observed. Three episodes of catheter occlusion requiring replacement occurred in two patients for an observed rate of 0.16 per 1,000 catheter patient days for thrombotic occlusion. One patient required port replacement and another patient required replacement twice. In 13 out of 15 patients, the median duration of port use was 45 months. No episode of catheter\u2010associated bacteremia or catheter tunnel infections was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Comparing our results with other reported studies of CVAD\u2010associated complications in patients with SCD, we observed a lower rate of complications with the use of Cathlink 20 ports. These findings may be partly related to the design of the port and partly to a dedicated group of nurses accessing the ports in a controlled environment in an apheresis unit. Pediatr Blood Cancer 2005;44:669\u2013672. \u00a9 2005 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20252","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T07:17:00Z","timestamp":1107847020000},"page":"669-672","source":"Crossref","is-referenced-by-count":28,"title":["Cathlink\u00ae 20: A subcutaneous implanted central venous access device used in children with sickle cell disease on long\u2010term erythrocytapheresis\u2014a report of low complication rates"],"prefix":"10.1002","volume":"44","author":[{"given":"Ashok","family":"Raj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Bertolone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon","family":"Bond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audria","family":"Denker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,2,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90057-5"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3886(00)00042-4"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10047"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.1996.00154.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199511000-00011"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2729.2001.00153.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200210000-00009"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6109(16)45880-9"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830290303"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00331-7"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/315081"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20252","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T19:42:14Z","timestamp":1696794134000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,7]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,6,15]]}},"alternative-id":["10.1002\/pbc.20252"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20252","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,7]]}}}